We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 15, 2022

Enzalutamide With Samotolisib in Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Clin. Cancer Res 2022 Jun 01;28(11)2237-2247, CJ Sweeney, IJ Percent, S Babu, JL Cultrera, BA Mehlhaff, OB Goodman, DS Morris, ID Schnadig, C Albany, ND Shore, PR Sieber, SC Guba, W Zhang, V Wacheck, GP Donoho, AM Szpurka, S Callies, BK Lin, JC Bendell

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading